Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

umbilical cord blood-derived CD4+/CD25+ T-regulatory cells CK0801

A preparation composed of allogeneic umbilical cord blood (UCB)-derived, ex vivo expanded and enhanced CD4+/CD25+ T-regulatory cells (Tregs) with potential immunomodulatory activity. Upon administration, the UCB-derived CD4+/CD25+ Tregs CK0801 may promote immunologic homeostasis and prevent autoimmunity by suppressing self-reactive T cells. This may induce tolerance to allogeneic organ transplants, prevent graft-versus-host disease (GvHD), and suppress autoimmune pathology.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	UCB-derived CD4+CD25+ Tregs CK0801
Code name:	CK 0801 CK-0801 CK0801

umbilical cord blood-derived CD4+/CD25+ T-regulatory cells CK0801

Search NCI's Drug Dictionary